Work

Two Year Outcomes of Short-Term Potent Androgen Blockade and Definitive Radiation for Intermediate to High Risk Localized Prostate Cancer

Year: 2018

Type: article

Source: International Journal of Radiation Oncology*Biology*Physics

DOI: 10.1016/j.ijrobp.2018.06.256

Authors: B.F. Koontz, K.E. Hoffman, P. Healy, D.J. George, M.R. Harrison, T. Zhang, W.R. Lee, W.R. Berry, T.J. Pugh, L. Bratt, B. Hobbs, S. Halabi, P.G. Corn, A. Armstrong, K. Shobe, B. Tojong, B. Thornburg, K. Brummer, D. Allen

Institutions: Duke University, Duke Cancer Institute, The University of Texas MD Anderson Cancer Center

Language: English

Topic: Prostate Cancer Diagnosis and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Pfizer, Sanofi, Gilead Sciences, Celgene, Vanderbilt University, Augmenix, Exelixis, Acceleron, G1 Therapeutics, Eisai, Astellas Pharma, Active Biotech, Genentech

OpenAlex ID: W2897342635

FWCI:

Cites:

Cited by:

Related to: 10